Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro
- Posted on September 29, 2026
- By Bing News
- 3 Views
- 1 min read
In brief
Generating AI summary…
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro
COPENHAGEN, Sept 29 (Reuters) - Novo Nordisk said on Tuesday a real-world study found that adults with type 2 diabetes who took an escalated dose of its diabetes drug, Ozempic, had a lower risk of major cardiovascular events compared to those who switched to Eli Lilly's Mounjaro. The company said patients who escalated their dose of Ozempic to 2 milligrams (mg) from 1 mg saw a statistically
